Orthofix MedicalOFIX
Recorded

Orthofix Medical 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration34 minParticipants8

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello, everyone. Thank you for joining us, and welcome to the Orthofix Q3 2026 earnings call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to Julie Dewey.

Julie DeweyChief IR and Communications Officer

Please go ahead. Thank you, and good morning, everyone.

Julie DeweyChief IR and Communications Officer

Welcome to Orthofix's third quarter 2026 earnings call. I'm Julie Dewey, Orthofix's Chief IR and Communications Officer. Joining me today are our President and Chief Executive Officer, Massimo Calafiore, and our Chief Financial Officer, Julie Andrews. Earlier today, Orthofix released financial results for the third quarter ended September 30, 2026. The press release and supplemental presentation are available on our investor relations website. A replay of this call will be posted shortly after we conclude. Before we begin, please note that our remarks include forward-looking statements. These statements involve risks and uncertainties, and actual results may differ materially. All statements other than those of historical facts are forward-looking statements. We do not undertake any obligation to revise or update such forward-looking statements, except as required by law.

Julie DeweyChief IR and Communications Officer

Factors that could cause actual results to differ materially are discussed in our most recent filings with the SEC and may be included in our future filings with the SEC. We will also reference certain non-GAAP financial measures during today's call, including certain growth rates presented on a pro forma constant currency basis and excluding discontinued M6 artificial disc product lines. Reconciliations to the most directly comparable U.S. GAAP measures and additional information are included in our press release and supplemental materials. Here's today's agenda. Massimo will begin with business performance and operational highlights. Julie Andrews will then review our financial results and guidance. After that, we'll open the call for questions. With that, I'll turn the call over to Massimo to discuss our third quarter performance.

Massimo CalafiorePresident and CEO

Massimo? Thank you, Julie, and good morning, everyone.

Massimo CalafiorePresident and CEO

I appreciate you joining us today. While third quarter results were below our expectation, we saw continued strength in Limb Reconstruction and Therapeutic Solutions, and further stabilization in U.S. Biologics. In U.S. Spine, market softness and unplanned supplier delays created inventory and instrument set constraints. We have a clear recovery plan and are accelerating actions to improve execution and position the business for stronger performance. We are concentrating resources behind our strongest partners and highest value technology, simplifying the portfolio and aligning costs with a more focused business. These actions are intended to establish a stronger foundation for growth, profitability, and cash generation over time. To recap this action in more detail, first, we are concentrating resources behind our strongest commercial partners. We are accelerating exits from non-strategic, lower-performing relationships and redeploying instrument sets to faster-growing core distributors.

Massimo CalafiorePresident and CEO

These distributors now generate around 80% of U.S. spinal implant revenue, with a similar concentration among core products. We have already seen this strategy work in markets where we consolidated distribution around stronger partners. Our core partners' consigned assets turn around 20% faster than the loaner-heavy model used by many distributors we are exiting. This allows existing sets to support more procedures and revenue with less incremental investment. Second, we are simplifying our product portfolio and concentrating investment behind our highest value technologies. We are focusing inventory, capital, and commercial support on differentiated platforms with the greatest growth potential, including VIRATA. We continue to expect the full market launch of our VIRATA spinal implant system for open procedures later in the fourth quarter. Third, we are aligning costs and organizational resources with a more focused business.

Massimo CalafiorePresident and CEO

As we simplify the network and portfolio, we expect to reduce support costs and redirect resources towards the opportunities with the strongest growth and return potential. Fourth, we are focusing our innovation pipeline on technologies with the greatest potential to drive adoption and long-term growth. That includes VIRATA and further integration of our enabling technologies, such as the 7D navigation system, for which we received two 510(k) clearances this quarter covering additional software enhancements. The combination of these actions and the supplier delays are creating near-term net sales pressure as we exit lower-value business. We expect this transition to unfold over the coming quarters, with the anticipated fourth-quarter impact reflected in our updated guidance. We are carefully sequencing relationship exits and asset redeployment with the goal of maintaining surgical support and product availability, while positioning our strongest partners for growth. We expect progress in stages.

Massimo CalafiorePresident and CEO

First, we anticipate improved inventory and instrument set availability and utilization among core distributors. Next, we expect stronger growth from core products and partners. Over time, we expect those improvements to support better channel productivity, profitability, and cash conversion. While spine remains our most immediate focus, we continue to make progress in several other parts of the portfolio. U.S. biologics net sales were roughly flat sequentially, despite the typical seasonal softness, providing another sign of stabilization. October offered another encouraging data point, as the business returned to positive year-over-year growth. Our priority is to build on this momentum through stronger account execution, higher utilization, and continued focus on priority products, including OsteoCove. In global Limb Reconstruction, growth in the quarter was driven by strong international demand and continued adoption of FITBONE and TRUELOK Elevate.

Massimo CalafiorePresident and CEO

These two platforms are driving the majority of the franchise's growth and address large unpenetrated markets where we believe our differentiated technology can support sustained growth. In the U.S., we remain focused on increasing distributor productivity and expanding market development activities to convert clinical interest into broader adoption and net sales growth. As those capabilities mature, we expect improved U.S. growth and greater predictability. We also continue to invest in innovation across Limb Reconstruction. In September, we submitted a 510(k) pre-market notification for an automated version of the TRUELOK Elevate system, designed to improve the patient experience and support a key growth driver. We are also pursuing potential additional indications, including diabetic foot ulcer, a large and underserved market where we believe our core technologies may have broader clinical application. These investments are intended to expand our addressable market, strengthen our clinical differentiation, and support long-term value creation.

Massimo CalafiorePresident and CEO

Turning to Therapeutic Solutions, the business delivered 4% volume growth, which was above market growth, while maintaining attractive margins and strong cash generation, reinforcing its role as a stable contributor to the portfolio. Our priority is to improve prescription conversion and use digital capabilities, including AccelStim 2.0 and STIM onTrack, with the goal of strengthening physician and patient engagement while maintaining investment discipline. Taken together, our immediate priority is improving U.S. spine execution while sustaining momentum across the stronger areas of our portfolio. Across the business, we remain focused on disciplined execution, thoughtful capital allocation, and measurable progress. With that, I will turn the call over to Julie Andrews to review our third-quarter financial results and outlook.

Julie AndrewsCFO

Thank you, Massimo, and good morning. For purposes of consistency, the growth rates I will reference today are on a pro forma constant currency basis and exclude the discontinued M6 product lines. Third-quarter reported net sales were $207.9 million, an increase of 2.3% year-over-year. Growth in Limb Reconstruction and Therapeutic Solutions helped offset weaker performance in spine. The drivers varied by business. Let me walk you through the quarter in more detail. Global spinal implants, biologics, and enabling technologies generated $107.4 million in net sales, a decrease of approximately 1% versus the prior year period. Global spine fixation net sales increased 1% on a constant currency basis, while U.S. spine fixation declined 5%. Performance was affected by a softer market-driven procedural environment and continued declines among smaller distributors.

Julie AndrewsCFO

In addition, supplier delays and instrument set constraints limited our ability to consistently support demand among our top 30 distributors, whose pace of growth weakened but remained above the market. The financial effects of these actions are reflected in our updated guidance, which I will discuss shortly. In biologics, stabilization in the U.S. continued in the third quarter, with net sales roughly flat sequentially despite typical seasonal softness. While the recent trend is encouraging, we recognize that sustained improvement is still needed. Therapeutic Solutions generated $64 million in net sales, up 4% year-over-year. The business continued to deliver steady revenue growth, strong margins, and cash generation. Global Limb Reconstruction delivered net sales of $36.4 million in the third quarter, an increase of 9% on a constant currency basis. Growth was driven by strong international demand and continued adoption of FITBONE and TRUELOK Elevate.

Julie AndrewsCFO

U.S. growth was essentially flat in the quarter, but we believe the underlying trajectory and portfolio mix are improving. FITBONE and TRUELOK Elevate each grew in excess of 20%, providing encouraging evidence that the transition toward high-growth Limb Reconstruction opportunities is gaining traction. The remaining pressure was concentrated in a limited number of product lines and distributor relationships rather than across the franchise. Moving down the P&L, non-GAAP adjusted gross margin was 70.7%, reflecting an unfavorable geographic mix during the quarter. Adjusted EBITDA was $26 million, or 12.5% of pro forma net sales, compared with $24.6 million, or 12.1% in the prior year period. The improvement primarily reflected continued cost discipline and resource alignment, partially offset by lower spine revenue, unfavorable geographic mix, and reduced operating leverage. We ended the quarter with $86.9 million in cash equivalents, and restricted cash.

Julie AndrewsCFO

The change in cash primarily reflected working capital timing, investment instrument sets ahead of the commercial launch of VIRATA, and inventory to support our European MDR strategy. Let me now turn to our updated full-year outlook. Again, all measures are provided on a non-GAAP pro forma basis, reflect current foreign currency exchange rates, and exclude the discontinued M6 product lines. Our outlook does not contemplate any additional exchange rate changes during the remainder of the year. We now expect full-year 2026 pro forma net sales in the range of $825 million-$830 million. The revised guidance reflects third-quarter performance, continued softness in the spine market, and the anticipated impact of accelerated actions to improve U.S. spine commercial execution, inventory and instrument set availability, and productivity. It also reflects the timing of international Limb Reconstruction orders and foreign exchange headwinds.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day